Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, and Policy Development of Medical Products for Ongoing Public Health Activities, U01 Clinical Trial Not Allowed
ID: 353528Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $700K

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353528

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-036.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 15, 2024 12:00 AM
  4. 4
    Due Jun 17, 2024 12:00 AM
Description

The Food and Drug Administration (FDA) has posted a grant opportunity titled "Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, and Policy Development of Medical Products for Ongoing Public Health Activities, U01 Clinical Trial Not Allowed". This opportunity falls under the category of Food and Nutrition and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching.

The purpose of this grant is to solicit applications from neutral, independent institutions and organizations to support meetings and activities that bring together multiple stakeholders to explore, research, and address issues related to medical products, policy, and surveillance methods and systems. The grant will support the design, planning, execution, synthesis, summary, and communication of findings from these forums to a broad range of organizations and individuals.

The grant has an award ceiling of $700,000 and an estimated total program funding of $700,000. It is expected that one award will be granted. The closing date for applications is June 17, 2024, and the archive date is July 17, 2024.

The grant is open to various types of Higher Education Institutions, including Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and regional organizations.

For more information and to apply for the grant, please visit the following link: RFA-FD-24-036 Funding Opportunity Announcement. If you have any questions, you can contact Terrin Brown at terrin.brown@fda.hhs.gov.

Point(s) of Contact
terrin.brown@fda.hhs.gov
Files
Title
Posted
RFA-FD-24-036.html
4/20/2024
Similar Opportunities
Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant for the Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F). This grant aims to support the advancement of a nationally Integrated Food Safety System (IFSS) by assisting state manufactured food regulatory programs in achieving and maintaining conformance with the Manufactured Food Regulatory Program Standards (MFRPS). The MFRPS are designed to ensure that state manufactured food regulatory programs implement a high-quality regulatory framework that emphasizes mutual reliance and enhances food safety. These program standards provide a uniform basis for measuring and improving the performance of manufactured food regulatory programs in the United States, with the goal of reducing foodborne illness hazards in food manufacturing facilities. In addition to the MFRPS, the grant also supports other initiatives such as the Food Protection Task Force (FPTF), which aims to establish and/or support a statewide food protection system that addresses specific needs and maximizes public health protection. The FPTF promotes collaboration and cooperation among federal, state, local, tribal, and territorial agencies, industry, academia, and consumers to improve food safety. Furthermore, the grant includes funding for the development of state-driven dietary supplement regulatory frameworks and programs. The objective is to advance the adoption and implementation of current Good Manufacturing Practices (cGMPs) for Dietary Supplements Rule, with a focus on training and program development activities. Lastly, the grant offers support for special projects that promote innovation and integration in the IFSS using the MFRPS framework. These projects address emerging food safety priorities and require sharing project deliverables and resources with other programs. The grant is open to state, tribal, and territorial manufactured food regulatory programs that meet the eligibility requirements, including having a long-term food nonpublic information sharing agreement with the FDA or agreeing to enter into such an agreement. The funding tracks include MFRPS Development and MFRPS Maintenance, with different funding levels and options based on the number of years of funding received under past MFRPS cooperative agreements. Applicants are encouraged to apply for cooperative agreement assistance that aligns with their jurisdiction's needs in terms of funding amounts and project years. The grant has an award ceiling of $1,285,000 and an award floor of $340,000, with an expected number of four awards to be granted. For more information and to apply for the grant, interested parties can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610.
Manufactured Foods Flexible Funding Model (MF-FFM)
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a Manufactured Foods Flexible Funding Model (MF-FFM) through a Cooperative Agreement. This funding opportunity falls under the category of Consumer Protection and is forecasted as a discretionary grant. The purpose of this grant is to advance efforts for a nationally integrated food safety system (IFSS) by supporting various programs such as Manufactured Food Regulatory Program Standards (MFRPS), dietary supplement safety and oversight programs, improved state compliance and enforcement infrastructure, and state Food Protection Task Force (FPTF) programs. The MFRPS aim to ensure that State manufactured food regulatory programs develop and maintain best practices for a high-quality regulatory program. These program standards are intended to enhance food safety by establishing a uniform basis for measuring and improving the performance of manufactured food regulatory programs in the United States. The grant is open to State, local, territorial, and tribal agencies, as well as non-profit training entities that collaborate with one or more institutions of higher education. The competition is limited to these national organizations/associations due to their responsibility and authority for food regulation in their respective jurisdictions. Awardees must have or be willing to enter into an information disclosure agreement with the FDA and will be required to have at least a commissioning certificate (or be willing to procure one) to facilitate information sharing between other States and the FDA. The FDA expects to make approximately 50 awards for this grant opportunity. The estimated project start date is July 1, 2023, and the fiscal year for this grant is 2023. For more information or to contact the grantor, Gordana Zuber, the Grant Management Specialist, please use the following email: gordana.zuber@fda.hhs.gov or call 301-348-1747.
Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional". This funding opportunity falls under the category of Consumer Protection and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of the impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products. The grant has an award ceiling of $500,000 and an award floor of $250,000. It is expected that there will be 2 awards given. The eligible applicants for this grant opportunity are unrestricted, meaning any applicant organization may submit an application. However, each application must be scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. For more information and to apply for this grant opportunity, you can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The last updated date for this grant opportunity is November 30, 2023.
Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is announcing a Funding Opportunity Announcement (FOA) for a Cooperative Agreement titled "Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)". This opportunity falls under the category of Food and Nutrition. The aim of this grant is to improve the safety of human drugs with potential nitrosamine impurity liabilities. The FDA is seeking proposals to conduct research, development, and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The grant recipient will also assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends. The grant amount for this opportunity is set at $350,000, with an expected number of awards being 1. There is no cost sharing or matching requirement for applicants. The eligible applicants are unrestricted, meaning any organization can apply. However, applicant organizations may submit more than one application, provided that each application is scientifically distinct. For more information and to apply, interested parties can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The deadline for submission is November 30, 2023.
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required". This grant aims to fund clinical trials of products that evaluate efficacy and/or safety in order to support a new indication or change in labeling to address unmet needs in rare diseases or conditions. The FDA expects that by funding collaborative, efficient, and/or innovative clinical trials, the number of approved treatments for rare diseases will increase, thereby having a positive impact on rare disease drug development. The grant does not require cost sharing or matching and falls under the category of Science and Technology and other Research and Development. The grant has a closing date of September 22, 2024, and the award ceiling is $650,000, with a minimum award floor of $200,000. It is expected that 20 awards will be granted. Eligible applicants include various types of organizations such as higher education institutions, nonprofits, for-profit organizations, governments, and foreign institutions. For more information, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html). For any inquiries, the grantor contact is Shashi Malhotra, a Grants Management Specialist, who can be reached at shashi.malhotra@fda.hhs.gov or by phone at 2404027592.